Differences in the behavior of advanced glycation end products and advanced oxidation protein products in patients with allergic rhinitis

Journal of Investigational Allergology and Clinical Immunology

Volumn 23, Issue 2, 2013, Pages 101-106

  Di Lorenzo, G ^a   Minciullo, P L ^b   Leto Barone, M S ^a   La Piana, S ^a   La Porta, G ^a   Saija, A ^c   Gangemi, S ^b,d  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Advanced glycation end products; Advanced oxidation protein products; Allergic rhinitis; Allergy; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; BIOLOGICAL MARKER; IMMUNOGLOBULIN E;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EOSINOPHIL; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SPECTROFLUOROMETRY; SPECTROPHOTOMETRY;

EID: 84875410495     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Holguin F, Fitzpatrick A. Obesity, asthma, and oxidative stress. J Appl Physiol. 2010;108:754-9.
2. Bowler RP, Crapo JD. Oxidative stress in allergic respiratory diseases. J Allergy Clin Immunol. 2002;110:349-56.
3. Iijima MK, Kobayashi T, Kamada H, Shimojo N. Exposure to ozone aggravates nasal allergy-like symptoms in guinea pigs. Toxicol Lett. 2001;123:77-85.
4. Riediker M, Monn C, Koller T, Stahel WA, Wuthrich B. Air pollutants enhance rhinoconjunctivitis symptoms in pollen-allergic individuals. A nn Allergy Asthma Immunol. 2001;87:311-8.
5. Akbay E, Arbaù H, Uyar Y, Oztürk K. Oxidative stress and antioxidant factors in pathophysiology of allergic rhinitis. Kulak Burun Bogaz Ihtis Derg. 2007;17:189-96.
6. Li XL, Zhou AG, Zhang L, Chen WJ. Antioxidant status and immune activity of glycyrrhizin in allergic rhinitis mice. Int J Mol Sci. 2011;12:905-16.
7. Ogasawara H, Yoshimura S, Kumoi T. Hydrogen peroxide generation by eosinophils in allergic rhinitis. Auris Nasus Larynx. 1991;18:133-43.
8. Tanou K, Koutsokera A, Kiropoulos TS. Inflammatory and oxidative stress biomarkers in allergic rhinitis: the effect of smoking. Clin Exp Allergy. 2009;39:345-53.
9. Długosz A, Liebhart J, Piotrowska D, Dor A, Liebhart E. Markers of oxidative balance and concentration of selected metals in pollinotics. Przegl Lek. 2005;62:1328-31.
10. Emin O, Hasan A, Aysegul D, Rusen D. Total antioxidant status and oxidative stress and their relationship to total IgE levels and eosinophil counts in children with allergic rhinitis. J Investig Allergol Clin Immunol. 2012;22:188-92.
11. Sadowska-Woda I, Sychta B, Rachel M, Bieszczad-Bedrejczuk E. Protective effect of desloratadine against oxidative stress in human erythrocytes in vitro. Environ Toxicol Pharmacol. 2010;30:141-46.
12. Gratziou C, Rovina N, Makris M, Simoes DC, Papapetropoulos A, Roussos C. Breath markers of oxidative stress and airway inflammation in Seasonal Allergic Rhinitis. Int J Immunopathol Pharmacol. 2008;21:949-57.
13. Celik M, Tuncer A, Soyer OU, Saçkesen C, Tanju Besler H, Kalayci O. Oxidative stress in the airways of children with asthma and allergic rhinitis. Pediatr Allergy Immunol. 2012;23:556-61.
14. Bakkeheim E, Mowinckel P, Carlsen KH, Burney P, Carlsen KC. Altered oxidative state in schoolchildren with asthma and allergic rhinitis. Pediatr Allergy Immunol. 2011;22:178-85.
15. Sagdic A, Sener O, Bulucu F, Karadurmus N, Özel HE, Yamanel L, Tasci C, Naharci I, Ocal R, Aydin A. Oxidative stress status and plasma trace elements in patients with asthma or allergic rhinitis. Allergol Immunopathol (Madr). 2011;39:200-5.
16. Jiao J, Zhang W, Meng N, Wang H, Zhang L. Changes of oxidative stress in peripheral serum of patients with allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010;45:455-8.
17. Kalousová M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J. Advanced glycoxidation end products in chronic diseases - clinical chemistry and genetic background. Mutat Res. 2005;579:37-46.
18. Piwowar A. Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property. Pol Merkuriusz Lek. 2010;28:166-9.
19. Miraglia N, Assennato G, Clonfero E, Fustinoni S, Sannolo N. Biologically effective dose biomarkers. G Ital Med Lav Ergon. 2004;26:298-301.
20. Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C, Ditta V, Martinelli N, Candore G, Mansueto P, Rini GB, Corrocher R, Caruso C. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in monotherapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34:259-67.
21. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl 86):8-160.
22. Di Lorenzo G, Mansueto P, Melluso M, Candore G, Colombo A, Pellitteri ME, Drago A, Potestio M, Caruso C. Allergic rhinitis to grass pollen: measurement of inflammatory mediators of mast cell and eosinophils in native nasal fluid lavage and in serum out of and during pollen season. J Allergy Clin Immunol. 1997;100:832-7.
23. Di Lorenzo G, Pacor ML, Amodio E, Leto-Barone MS, La Piana S, D'Alcamo A, Ditta V, Martinelli N, Di Bona D. Differences and similarities between allergic and nonallergic rhinitis in a large sample of adult patients with rhinitis symptoms. Int Arch Allergy Immunol. 2011;155:263-70.
24. Spatari G, Saitta S, Cimino F, Sapienza D, Quattrocchi P, Carrieri M, Barbaro M, Saija A, Gangemi S. Increased serum levels of advanced oxidation protein products and glycation end products in subjects exposed to low-dose benzene. Int J Hyg Environ Health. 2012;215:389-92.
25. Gangemi S, Allegra A, Aguennouz M, Alonci A, Speciale A, Cannavò A, Cristani M, Russo S, Spatari G, Alibrandi A, Musolino C. Relationship between advanced oxidation protein products, advanced glycation end products, and S-nitrosylated proteins with biological risk and MDR-1 polymorphisms in patients affected by B-chronic lymphocytic leukemia. Cancer Invest. 2012;30:20-6.
26. de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CG, Bijl M, Posthumus MD. Advanced glycation endproducts are increased n rheumatoid arthritis patients with controlled disease. Arthritis Res Ther. 2011;13(6):R205. Epub 2011 Dec 14.
27. Sternberg Z, Ostrow P, Vaughan M, Chichelli T, Munschauer F. AGE-RAGE in multiple sclerosis brain. Immunol Invest. 2011;40:197-205.
28. Wu L, Ma L, Nicholson LF, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med. 2010;105:329-36.
29. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon (carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest. 1999;104:103-13.
30. Anderson MM, Heinecke JW. Production of N(epsilon) (carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes. 2003;52:2137-43.
31. Marsche G, Frank S, Hrzenjak A, Holzer M, Dirnberger S, Wadsack C, Scharnagl H, Stojakovic T, Heinemann A, Oettl K. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res. 2009;104:750-7.
32. Tsukahara H, Shibata R, Ohta N, Sato S, Hiraoka M, Ito S, Noiri E, Mayumi M. High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress. Metabolism. 2003;52:1601-5.
33. Sathiyapriya V, Bobby Z, Vinod Kumar S, Selvaraj N, Parthibane V, Gupta S. Evidence for the role of lipid peroxides on glycation of hemoglobin and plasma proteins in non-diabetic asthma patients. Clin Chim Acta. 2006;366:299-303.
34. Tochino Y, Kanazawa H, Ichimaru Y, Asai K, Kyoh S, Hirata K. Nepsilon-(carboxymethyl)lysine, a major advanced glycation end product in exhaled breath condensate as a biomarker of small airway involvement in asthma. J Asthma. 2007;44:861-6.
35. Aksoy F, Demirhan H, Veyseller B, Yildirim YS, Ozturan O, Basinoùlu F. Advanced oxidation protein products as an oxidative stress marker in allergic rhinitis. Kulak Burun Bogaz Ihtis Derg. 2009;19:279-84.
36. Kanazawa H, Tochino Y, Kyoh S, Ichimaru Y, Asai K, Hirata K. Potential roles of pentosidine in age-related and diseaserelated impairment of pulmonary functions in patients with asthma. J Allergy Clin Immunol. 2011;127:899-904.
37. Reich M, Niess JH, Bär C, Zwacka G, Markert UR. Elevated nonspecific plasma proteins in allergic patients. J Investig Allergol Clin Immunol. 2003;13:60-5.